Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 2/2014

01.02.2014 | Original Paper

Detection of pelvic lymph node micrometastasis by real-time reverse transcriptase polymerase chain reaction in prostate cancer patients after hormonal therapy

verfasst von: Ding-yi Liu, Wei-mu Xia, Qi Tang, Jian Wang, Min-wei Wang, Ying Wang, Shu-jun Wang, Yong-feng Ye, Wen-long Zhou, Yuan Shao

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Objective

To determine the feasibility of prostatic-specific antigen (PSA) mRNA and prostatic-specific membrane antigen (PSMA) mRNA measurement in detection of pelvic lymph node (PLN) micrometastasis for prostate cancer (PCa) after hormonal therapy (HT).

Methods

Fifty-four patients diagnosed as high risk localized PCa were given HT for 3 months before radical prostatectomy. Under bipedal lymphangiography, a needle was punctured into involved lymph nodes (LN) and aspirated lymphatic fluid was obtained preoperatively. The expression of PSA mRNA and PSMA mRNA in aspirated fluid was assessed by a fully quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR) and also in LN specimens from pelvic lymphadenectomy during prostatectomy.

Results

Median follow-up was 36 months (range 18–58 months). Without histological evidence of PLN metastasis, twelve patients showed positive PSA and/or PSMA mRNA expressions and regarded as having micrometastases to PLNs. Biochemical recurrence (BCR) rate and interval between prostatectomy and BCR in patients with micrometastases (group B) were not significantly different to histologically proven PLN metastatic patients (group A) (58.3 vs. 83.3 %, P = 0.26; 10.9 vs. 9.2 months, P = 0.29, respectively), but significantly different to those with no PLN involvement (group C) (58.3 vs. 11.1 %, P = 0.002; 10.9 vs. 21.3 months, P < 0.001, respectively). Kaplan–Meier analysis showed both groups A and B had significantly lower non-BCR rate than group C (P < 0.001, P < 0.001, respectively).

Conclusions

For PCa patients receiving HT, measurement of PSA mRNA and PSMA mRNA in aspirated PLN fluid by real-time RT-PCR could effectively detect PLN micrometastases without surgical intervention.
Literatur
Zurück zum Zitat Bader P, Burkhard FC, Markwalder R, Studer UE (2003) Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 169(3):849–854PubMedCrossRef Bader P, Burkhard FC, Markwalder R, Studer UE (2003) Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 169(3):849–854PubMedCrossRef
Zurück zum Zitat Briganti A, Chun FK, Salonia A et al (2006) Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol 49(6):1019–1026PubMedCrossRef Briganti A, Chun FK, Salonia A et al (2006) Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol 49(6):1019–1026PubMedCrossRef
Zurück zum Zitat Briganti A, Blute ML, Eastham JH et al (2009a) Pelvic lymph node dissection in prostate cancer. Eur Urol 55(6):1251–1265PubMedCrossRef Briganti A, Blute ML, Eastham JH et al (2009a) Pelvic lymph node dissection in prostate cancer. Eur Urol 55(6):1251–1265PubMedCrossRef
Zurück zum Zitat Briganti A, Karnes JR, Da Pozzo LF et al (2009b) Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N + patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 55(2):261–270PubMedCrossRef Briganti A, Karnes JR, Da Pozzo LF et al (2009b) Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N + patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 55(2):261–270PubMedCrossRef
Zurück zum Zitat Catalona WJ, Smith DS (1998) Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol 160(6 Pt 2):2428–2434PubMed Catalona WJ, Smith DS (1998) Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol 160(6 Pt 2):2428–2434PubMed
Zurück zum Zitat Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, Bostwick DG (2001) Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 91(1):66–73PubMedCrossRef Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, Bostwick DG (2001) Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 91(1):66–73PubMedCrossRef
Zurück zum Zitat Ferrari AC, Stone NN, Kurek R et al (2006) Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment. J Clin Oncol 24(19):3081–3088PubMedCrossRef Ferrari AC, Stone NN, Kurek R et al (2006) Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment. J Clin Oncol 24(19):3081–3088PubMedCrossRef
Zurück zum Zitat Gervasi LA, Mata J, Easley JD et al (1989) Prognostic significance of lymph nodal metastases in prostate cancer. J Urol 142(2 Pt 1):332–336PubMed Gervasi LA, Mata J, Easley JD et al (1989) Prognostic significance of lymph nodal metastases in prostate cancer. J Urol 142(2 Pt 1):332–336PubMed
Zurück zum Zitat Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD (1996) Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 155(1):213–219PubMedCrossRef Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD (1996) Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 155(1):213–219PubMedCrossRef
Zurück zum Zitat Gleave M, La Bianca SE, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD (2000) Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up. Urology 56(2):289–294PubMedCrossRef Gleave M, La Bianca SE, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD (2000) Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up. Urology 56(2):289–294PubMedCrossRef
Zurück zum Zitat Gleave ME, Goldenberg SL, Chin JL et al (2001) Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 166(2):500–506PubMedCrossRef Gleave ME, Goldenberg SL, Chin JL et al (2001) Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 166(2):500–506PubMedCrossRef
Zurück zum Zitat Heidenreich A, Varga Z, Von Knobloch R (2002) Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy prostatectomy: high incidence of lymph node metastasis. J Urol 167(4):1681–1686PubMedCrossRef Heidenreich A, Varga Z, Von Knobloch R (2002) Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy prostatectomy: high incidence of lymph node metastasis. J Urol 167(4):1681–1686PubMedCrossRef
Zurück zum Zitat Heidenreich A, Ohlmann CH, Polyakov S (2007) Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 52(1):29–37PubMedCrossRef Heidenreich A, Ohlmann CH, Polyakov S (2007) Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 52(1):29–37PubMedCrossRef
Zurück zum Zitat Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer, I: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59(1):61–71PubMedCrossRef Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer, I: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59(1):61–71PubMedCrossRef
Zurück zum Zitat Hovels AM, Heesakkers RA, Adang EM et al (2008) The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63(4):387–395PubMedCrossRef Hovels AM, Heesakkers RA, Adang EM et al (2008) The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63(4):387–395PubMedCrossRef
Zurück zum Zitat Katz S, Rosen M (2006) MR imaging and MR spectroscopy in prostate cancer. management. Radiol Clin North Am 44(5):723–734PubMedCrossRef Katz S, Rosen M (2006) MR imaging and MR spectroscopy in prostate cancer. management. Radiol Clin North Am 44(5):723–734PubMedCrossRef
Zurück zum Zitat Köllermann J, Weikert S, Schostak M et al (2008) Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. J Clin Oncol 26(30):4928–4933PubMedCrossRef Köllermann J, Weikert S, Schostak M et al (2008) Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. J Clin Oncol 26(30):4928–4933PubMedCrossRef
Zurück zum Zitat Lee HH, Warde P, Jewett MA (1999) Neoadjuvant hormonal therapy in carcinoma of the prostate. BJU Int 83(4):438–448PubMedCrossRef Lee HH, Warde P, Jewett MA (1999) Neoadjuvant hormonal therapy in carcinoma of the prostate. BJU Int 83(4):438–448PubMedCrossRef
Zurück zum Zitat Miyake H, Kurahashi T, Hara I, Takenaka A, Fujisawa M (2007a) Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy. BJU Int 99(2):315–320PubMedCrossRef Miyake H, Kurahashi T, Hara I, Takenaka A, Fujisawa M (2007a) Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy. BJU Int 99(2):315–320PubMedCrossRef
Zurück zum Zitat Miyake H, Hara I, Kurahashi T, Inoue T, Eto H, Fujisawa M (2007b) Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase polymerase chain reaction targeting prostate-specific antigen and prostate-specific membrane antigen genes. Clin Cancer Res 13(4):1192–1197PubMedCrossRef Miyake H, Hara I, Kurahashi T, Inoue T, Eto H, Fujisawa M (2007b) Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase polymerase chain reaction targeting prostate-specific antigen and prostate-specific membrane antigen genes. Clin Cancer Res 13(4):1192–1197PubMedCrossRef
Zurück zum Zitat Naiki T, Kawai N, Okamura T et al (2012) Neoadjuvant hormonal therapy is a feasible option in laparoscopic radical prostatectomy. BMC Urol 12:36–41PubMedCentralPubMedCrossRef Naiki T, Kawai N, Okamura T et al (2012) Neoadjuvant hormonal therapy is a feasible option in laparoscopic radical prostatectomy. BMC Urol 12:36–41PubMedCentralPubMedCrossRef
Zurück zum Zitat Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE (2008) Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 54(2):344–352PubMedCrossRef Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE (2008) Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 54(2):344–352PubMedCrossRef
Zurück zum Zitat Terakawa T, Miyake H, Kurahashi T et al (2009) Improved sensitivity for detecting micrometastases in pelvic lymph nodes by real-time reverse transcriptase polymerase chain reaction (RT-PCR) compared with conventional RT-PCR in patients with clinically localized prostate cancer undergoing radical prostatectomy. BJU Int 103(8):1074–1078PubMedCrossRef Terakawa T, Miyake H, Kurahashi T et al (2009) Improved sensitivity for detecting micrometastases in pelvic lymph nodes by real-time reverse transcriptase polymerase chain reaction (RT-PCR) compared with conventional RT-PCR in patients with clinically localized prostate cancer undergoing radical prostatectomy. BJU Int 103(8):1074–1078PubMedCrossRef
Zurück zum Zitat Walsh PC, Partin AW, Epstein JI (1994) Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 152(5 Pt 2):1831–1836PubMed Walsh PC, Partin AW, Epstein JI (1994) Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 152(5 Pt 2):1831–1836PubMed
Zurück zum Zitat Weingartner K, Ramaswamy A, Bittinger A, Gerharz EW, Voge D, Riedmiller H (1996) Anatomical basis for pelvic lymphadenectomy in prostate cancer. results of an autopsy study and implications for the clinic. J Urol 156(6):1969–1971PubMedCrossRef Weingartner K, Ramaswamy A, Bittinger A, Gerharz EW, Voge D, Riedmiller H (1996) Anatomical basis for pelvic lymphadenectomy in prostate cancer. results of an autopsy study and implications for the clinic. J Urol 156(6):1969–1971PubMedCrossRef
Zurück zum Zitat Wolf JS Jr, Cher M, Dall’era M, Presti JC Jr, Hricak H, Carroll PR (1995) The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol 153(3 Pt 2):993–999PubMedCrossRef Wolf JS Jr, Cher M, Dall’era M, Presti JC Jr, Hricak H, Carroll PR (1995) The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol 153(3 Pt 2):993–999PubMedCrossRef
Metadaten
Titel
Detection of pelvic lymph node micrometastasis by real-time reverse transcriptase polymerase chain reaction in prostate cancer patients after hormonal therapy
verfasst von
Ding-yi Liu
Wei-mu Xia
Qi Tang
Jian Wang
Min-wei Wang
Ying Wang
Shu-jun Wang
Yong-feng Ye
Wen-long Zhou
Yuan Shao
Publikationsdatum
01.02.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 2/2014
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-013-1558-2

Weitere Artikel der Ausgabe 2/2014

Journal of Cancer Research and Clinical Oncology 2/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.